TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34988917
Drug: Insulin intensification
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin intensification (increase in insulin dose, addition of new insulin, increase in insulin injection frequency)
Study: 34988917
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in insulin dose
Study: 34988917
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of new insulin
Study: 34988917
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in insulin injection frequency
Study: 34989180
Drug: Felcisetrag 0.2-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felcisetrag 0.2-mg intravenous dose
Study: 34989180
Drug: Itraconazole 200-mg
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200-mg oral doses
Study: 34989842
Drug: Radiologic scores
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiologic scores for guiding individualized induction chemotherapy
Study: 34990408
Drug: Low-dose aerosol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aerosol (LD) AdHu5Ag85A
Study: 34990408
Drug: High-dose aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aerosol (HD) AdHu5Ag85A
Study: 34990408
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) injection of AdHu5Ag85A
Study: 34990778
Drug: Proton radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton radiation therapy (PRT) at a dose of 54 Gy relative biological effectiveness
Study: 34990810
Drug: Self-amplifying mRNA
Normalized name: mRNA-3705
DrugBank: mRNA-3705 (DB17668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-amplifying mRNA (SAM) vaccine delivered by lipid nanoparticles (LNPs); two doses administered.
Study: 34990810
Drug: Self-amplifying mRNA
Normalized name: mRNA-3705
DrugBank: mRNA-3705 (DB17668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-amplifying mRNA (SAM) vaccine; two doses administered.
Study: 34991141
Drug: BIC/FTC/TAF coformulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIC/FTC/TAF coformulated as a single daily pill for 28 days
Study: 34991511
Drug: Emotion regulation-enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emotion regulation-enhanced group treatment
Study: 34991660
Drug: Unmet medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unmet medication needs
Study: 34991660
Drug: Higher proportion
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher proportion of unmet medication needs
Study: 34991660
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no unmet medication needs)
Study: 34991688
Drug: Dubbing language
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dubbing language cinema-based therapy
Study: 34991701
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing (MI) and two mobile health (mHealth) components: oral health promotion messages and storytelling videos delivered using WhatsApp messenger
Study: 34991703
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral montelukast every 24 hours
Study: 34991937
Drug: PCSK9 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCSK9 inhibitors (PCSK9-I) therapy
Study: 34992051
Drug: Average daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average daily steps (Fitbit)
Study: 34992093
Drug: Andecaliximab monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andecaliximab monotherapy (800 mg IV Q2W)
Study: 34992093
Drug: Andecaliximab in
Normalized name: Andecaliximab
DrugBank: Andecaliximab (DB17564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andecaliximab in combination with nivolumab (800 mg IV Q2W)
Study: 34992118
Drug: Low-dose naltrexone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose naltrexone (LDN) 4.5 mg/day
Study: 34992372
Drug: Vortioxetine 10
Normalized name: vortioxetine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 10 mg or 20 mg
Study: 34992575
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment during on-hours
Study: 34992575
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment during off-hours
Study: 34992825
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy with camrelizumab, nab-paclitaxel, and carboplatin
Study: 34994093
Drug: 225 mg
Normalized name: tyrosine 225 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 mg of oral testosterone undecanoate (TLANDO) twice a day for 24 days
Study: 34994777
Drug: ST266 eye
Normalized name: ST266
DrugBank: ST266 (DB18614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST266 eye drops, 4 times daily for 28 days
Study: 34995128
Drug: Early locoregional
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early locoregional therapy (surgery and radiotherapy per standards for nonmetastatic disease)
Study: 34995128
Drug: Continued systemic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued systemic therapy
Study: 34995128
Drug: Early locoregional
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early locoregional therapy
Study: 34995204
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered via telehealth, 4 sessions over 5 weeks
Study: 34995818
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid (CS) eye drops monitored with Kali Drop device
Study: 34996114
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitor (SSRI) treatment for 6 weeks in addition to mood stabilizer
Study: 34996784
Drug: Antithrombotic treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic treatments
Study: 34996920
Drug: Direct-acting antivirals
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antivirals (DAA)
Study: 34997267
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplementation (55 mg elemental iron from ferrous sulphate, once daily for 3 months)
Study: 34997701
Drug: Odronextamab (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odronextamab (320 mg weekly)
Study: 34997701
Drug: Odronextamab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odronextamab (0.5 mg dose)
Study: 34997701
Drug: Odronextamab (1-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odronextamab (1-10 mg/L) in Raji xenograft tumor mouse model
Study: 34997825
Drug: Sodium zirconium
Normalized name: Sodium zirconium silicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sodium zirconium cyclosilicate (SZC) 5 g
Study: 34998033
Drug: Daily protein
Normalized name: Supra Clens Daily Protein Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily protein intake (DPI)
Study: 34998377
Drug: Multiplex PCR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiplex PCR test plus autoimmune antibody testing
Study: 34998377
Drug: mNGS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: mNGS plus autoimmune antibody testing
Study: 34998471
Drug: Camrelizumab 200
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab 200 mg once every 2 weeks plus apatinib 250 mg once daily for a 28-day cycle
Study: 39745702
Drug: Recombinant quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant quadrivalent influenza vaccine (RIV4)
Study: 34998605
Drug: Standard-dose quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose quadrivalent inactivated influenza vaccine (SD-IIV4)
Study: 34998740
Drug: Optimal combination
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal combination of AI-ECG outputs from pulmonary and handheld positions
Study: 34999659
Drug: Depleting therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depleting therapy in the past year
Study: 35000420
Drug: preCARDIA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: preCARDIA therapy for 12 or 24 hours
Study: 35001051
Drug: Nonanimal stabilized
Normalized name: nonanal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonanimal stabilized hyaluronic acid/dextranomer treatment
Study: 35002791
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine treatment for 12 weeks
Study: 35003094
Drug: Anti-IL1RAP antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-IL1RAP antibody (nadunolimab, CAN04)
Study: 35003503
Drug: Self-Administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-Administration of Auricular Acupuncture
Study: 35004718
Drug: Prescription intervention;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription intervention; details not available
Study: 35005393
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral methadone
Study: 35005411
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy-based bibliotherapy intervention
Study: 35005777
Drug: Antifungal treatment
Normalized name: TOLNAFTATE 10 mg in 1 mL TOPICAL LIQUID [Liquid Antifungal Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifungal treatment (oral or topical)
Study: 35005777
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events (treatment and control groups)
Study: 35007745
Drug: Hazelnut oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hazelnut oral immunotherapy (H-OIT)
Study: 35012889
Drug: VPM1002BC (intravesical
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPM1002BC (intravesical treatment, 6 weekly instillations followed by maintenance for 1 year)
Study: 35012889
Drug: VPM1002BC (intravesical
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPM1002BC (intravesical treatment)
Study: 35013456
Drug: ssCART-19 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ssCART-19 treatment in low tumor burden group
Study: 35013456
Drug: ssCART-19 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ssCART-19 treatment in high tumor burden group
Study: 35013456
Drug: ssCART-19 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ssCART-19 treatment
Study: 35014900
Drug: Reduced-dose deep
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose deep learning image reconstruction (DLIR)
Study: 35014900
Drug: Standard-dose filtered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose filtered back projection (FBP)
Study: 35014900
Drug: Both reduced-dose
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both reduced-dose DLIR and standard-dose FBP
Study: 35015819
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg IV every 3 weeks for up to 16 cycles) and Rituximab (375 mg/m2 IV weekly for 4 weeks in cycle 1 only)
Study: 35015828
Drug: Lupus anticoagulant
Normalized name: Lupus anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupus anticoagulant (LA)
Study: 35015879
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g FOS
Study: 35015879
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g acacia gum
Study: 35015879
Drug: 6.1 g
Normalized name: CHLOROXYLENOL 6.1 g in 1 L TOPICAL SOAP [Antibacterial Hand]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.1 g lactose and 1.5 g sucrose (control)
Study: 35015980
Drug: Daily exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily exposure to mild intermittent hypoxia
Study: 35016146
Drug: Oral D/L-Na-lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral D/L-Na-lactate
Study: 35016146
Drug: Intravenous iso-lactemic
Normalized name: iso-sulfan blue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iso-lactemic D/L-Na-lactate
Study: 35017154
Drug: Camrelizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab (200 mg every 3 weeks by intravenous infusion) and oral famitinib (20 mg once daily)
Study: 35017197
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment in mice
Study: 35018097
Drug: mirtazapine+SNRIs+physical therapies
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mirtazapine+SNRIs+physical therapies
Study: 35018342
Drug: Vagus Nerve
Normalized name: SUS SCROFA VAGUS NERVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vagus Nerve Stimulation Therapy (VNS Therapy)
Study: 35018370
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual plus fitness tracker (TAU+)
Study: 35018553
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg once daily (QD)
Study: 35018553
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg QD
Study: 35018553
Drug: Lorlatinib 75
Normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lorlatinib 75 mg QD
Study: 35018878
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of direct oral anticoagulant within four days of stroke onset
Study: 35018878
Drug: Delayed initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Delayed initiation of direct oral anticoagulant, 7 to 14 days from onset
Study: 35018878
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of direct oral anticoagulant
Study: 35018878
Drug: Delayed initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Delayed initiation of direct oral anticoagulant
Study: 35020185
Drug: Opioid taper
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid taper
Study: 35021863
Drug: Hepatic irradiation
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic irradiation with Yttrium-90 microspheres followed by immunotherapy with Ipilimumab and Nivolumab
Study: 35022035
Drug: Monocyte-Derived Dendritic-cell
Normalized name: MONOCYTE-DERIVED NEUTROPHIL CHEMOTACTIC FACTOR
DrugBank: Human Interleukin 8 (DB16456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monocyte-Derived Dendritic-cell Therapy (MDDCT)
Study: 35022321
Drug: ONC201 (625
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONC201 (625 mg orally weekly) in arm A (PC-PG)
Study: 35022321
Drug: ONC201 (625
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONC201 (625 mg orally weekly) in arm B (other neuroendocrine tumors)
Study: 35022321
Drug: ONC201 (625
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONC201 (625 mg orally on 2 consecutive days each week) in arm C (PC-PG)
Study: 35022322
Drug: oHSV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: oHSV treatment with NOTCH blockade
Study: 35022322
Drug: oHSV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: oHSV treatment
Study: 35022711
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of SARS-CoV-2 antibodies (IgA, IgM, IgG, and/or total Ig)
Study: 35022711
Drug: Absence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absence of SARS-CoV-2 antibodies
Study: 35022790
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with ACE inhibitors (ACEis)
Study: 35025062
Drug: Deucravacitinib (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deucravacitinib (3 mg twice daily, 6 mg twice daily, 12 mg once daily)
Study: 35025555
Drug: Smartphone-delivered attentional
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-delivered attentional bias modification (ABM) training for 13 days as an adjunct to smoking cessation treatment
Study: 35027038
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with glucarpidase
Study: 35027038
Drug: MTX-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX-based therapy
Study: 35027656
Drug: cfDNA positivity
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cfDNA positivity (≥10% tumor fraction by LPWGS) after two cycles of treatment
Study: 35027656
Drug: cfDNA negativity
Normalized name: CFDN
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cfDNA negativity (tumor-negative) after two cycles of treatment
Study: 35027752
Drug: Olpasiran (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olpasiran (9 mg or higher)
Study: 35027752
Drug: Olpasiran (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olpasiran (single doses)
Study: 35027752
Drug: Olpasiran (dose-escalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olpasiran (dose-escalation trial)
Study: 35028673
Drug: Antibiotics and
Normalized name: Antibiotics and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics and caffeine among preterm infants
Study: 35028673
Drug: General drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: General drug utilisation patterns
Study: 35028673
Drug: Non-evidence-based drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-evidence-based drugs
Study: 35028673
Drug: Rational drug
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational drug use
Study: 35030234
Drug: 200,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200,000 IU Vitamin A Supplementation (VAS) administered before and 4 weeks after measurement
Study: 35031227
Drug: Obinutuzumab 1000
Normalized name: obinutuzumab 1000 MG in 40 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obinutuzumab 1000 mg IV in cycle 1, followed by obinutuzumab plus atezolizumab 1200 mg IV for cycles 2-8, and atezolizumab only from cycle 9.
Study: 35031227
Drug: Obinutuzumab plus
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab plus atezolizumab 1200 mg IV
Study: 35031227
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg IV every 3 weeks (RP2D)
Study: 35031547
Drug: NT-I7 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-I7 (10 mg/kg on the final day of RT)
Study: 35033008
Drug: Neoadjuvant chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiation therapy (nCRT) using MRI guided radiotherapy (MRgRT) with 55 Gy in 25 fractions on Gross Tumor Volume (GTV) and 45 Gy in 25 fractions on drainage nodes, along with continuous chemotherapy with 5-fluoracil (5-FU) or oral capecitabine.
Study: 35033008
Drug: MRI guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI guided radiotherapy (MRgRT) with dose escalation based on early tumour regression index (ERI).
Study: 35033092
Drug: Raltegravir 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 1200 mg once daily (qd) as part of triple combined antiretroviral therapy (cART)
Study: 35033092
Drug: Raltegravir 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 1200 mg qd
Study: 35033182
Drug: Dexamethasone 20
Normalized name: dexamethasone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 20 mg on days 1-5, followed by dexamethasone 10 mg on days 6-10
Study: 35033182
Drug: Dexamethasone 6
Normalized name: dexamethasone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 6 mg administered once daily intravenously for 10 days
Study: 35033999
Drug: Nonbiologic disease-modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonbiologic disease-modifying antirheumatic drugs (nbDMARDs)
Study: 35034046
Drug: Budigalimab 250
Normalized name: Budigalimab
DrugBank: Budigalimab (DB16668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budigalimab 250 mg Q2W or 500 mg Q4W
Study: 35034080
Drug: Hypertension treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertension treatment at registration
Study: 35034080
Drug: Hypertension treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertension treatment at the end of the baseline visit
Study: 35034116
Drug: Weight Loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight Loss (WL) + higher NfL (>94.55 pg/mL, highest quartile)
Study: 35034116
Drug: Weight Loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight Loss (WL) + higher progranulin (>38.4 ng/mL, 3 higher quartiles)